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1  Introduction
Bacteriocins are ribosomally-synthesized antimicrobial 
peptides produced by prokaryotes. Even though they 
are expressed by a wide range of bacteria, the specific 
peptides secreted by Lactic Acid Bacteria (LAB) are of 
special interest because they are generally recognized 
as safe for human health. To this purpose, bacteriocin-
related toxicity has been investigated and no toxic effects 
has been reported so far [1, 2].
Bacteriocins produced by LAB can be classified 
in two main groups [3]: I) lanthionine-containing 
peptides, II) non-lantibiotic peptides. Both groups are 
in turn catalogued into subgroups. In particular, group 
II bacteriocins are categorized as: IIa) pediocin-like 
bacteriocins, IIb) two-component bacteriocins, IIc) cyclic 
bacteriocins and IId) peptides not assigned to any other 
subgroups. Subgroup IIa is the most widely studied, and 
the bacteriocins belonging to this group have awakened 
great interest for their possible biotechnological and 
medical applications in the near future [4–6]. Indeed, 
pediocin PA-1, the best-known subclass IIa peptide, is 
already being produced commercially in large quantities 
(ALTA 2431, Kerry Bioscience, Cork Ireland).
Enterocin CRL35 is a pediocin-like bacteriocin 
produced by Enterococcus mundtii CRL35, of which 
complete biosynthetic gene cluster has been cloned and 
sequenced [7). This bacteriocin is mainly active against 
food-borne pathogen Listeria monocytogenes, other 
closely related LAB strains [8] and Herpes virus simplex 
type 1 and 2 [9]. Enterocin CRL35 also exhibits a synergistic 
effect with some clinical antibiotics, thus suggesting 
possible clinical applications in addition to its promising 
use as a food preservative [10].
The sequencing of numerous genomes has allowed 
the analysis of open reading frames related to the 
production of antimicrobial substances.  Nevertheless, 
the purification at the peptide level still represents a 
key step for the elucidation of the molecular structure of 
antimicrobial compounds. As a matter of fact, preliminary 
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attempts aimed to express the enterocin CRL35 in E. coli 
BL21 consistently showed the production of recombinant 
peptide(s) with a rather low specific activity. Therefore, 
the scope of the present work was to purify large 
amounts of pure recombinant enterocin CRL35 in order 
to accomplish further characterization by matrix assisted 
laser desorption ionization-time of flight (MALDI-TOF) 
mass spectrometry (MS) and HPLC-electrospray (ESI)-Q-
TOF tandem MS (MS/MS). 
2  Experimental Procedures
2.1  Strains and culture media
Bacteriocinogenic E. coli cells were cultured in Lauria-
Bertani (LB) medium (Sigma, St Louis, MI, USA). 
Opportune antibiotics were added when needed. The 
natural enterocin CRL35 producer strain, E. mundtii CRL35 
was grown in LAPTg [11], meanwhile the sensitive strain 
L. innocua 7 was grown in TSB medium supplemented 
with yeast extracts and 7.5 µg/ml nalidix acid [12]. The E. 
coli strains tested for overexpressing enterocin CRL35 as 
well as plasmids used in this study are listed in Table 1. 
Plasmids were amplified and maintained in E. coli 
DH5α. When appropriate, the following antibiotics were 
used in E.coli cultures: 50 µg/ml ampicillin; 30 µg/ml 
chloramphenicol; 15 µg/ml tetracycline.
2.2  munA cloning strategy
munA gene was PCR-amplified using the following primers: 
munAF3 5´ CATGCCATGGGTAAATACTACGGTAATGGA 
3´ and munAR3 5´ CGGGATCCTTAACTTTTCCAACCAG 
3´, which encoded a NcoI and BamHI recognition sites 
respectively. The amplified fragment was purified by 
AccuPrep® PCR Purification Kit (Bioneer, Korea) and 
digested with the appropriated enzymes. Then, it was 
ligated into pET22b(+) vector (Novagen) linearized with 
the same enzymes. E. coli DH5α was transformed by 
Table 1: Strains and plasmids
Strains and Plasmids Genotype or relevant characteristics Reference
Listeria innocua 7 enterocin CRL35 sensitive strain INRA1
Enterococcus mundtii CRL35 enterocin CRL35 producer strain CERELA2 
Escherichia coli DH5α FˉΦ80dlacZΔM15Δ(lacZYA-argF) U169recA1 endA-
1supE4 hsdR17(rkˉmk+)thi-1gyrArelA1 (NalR)
BRL3
Escherichia coli BL21(DE3) pLysS F– ompT hsdSB(rB– mB–) gal dcm (DE3) pLysS (CamR) Novagen
Escherichia coli C41(DE3) pLysS BL21(DE3)-derivative (Miroux and Walker 1996)
Escherichia coli C43(DE3) pLysS BL21(DE3)-derivative (Miroux and Walker 1996)
Escherichia coli Rosetta(DE3) pLysS F– ompT hsdSB(rB– mB–) gal dcm (DE3) pLysSRARE2 (CamR) Novagen
Escherichia coli Origami(DE3) Δ(ara–leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE galK 
rpsL F'[lac+ lacI q pro] (DE3) gor522::Tn10 trxB pLysS (CamR, KanR, 
StrR, TetR)
Novagen
Escherichia coli Rosetta-gami 2(DE3) Δ(ara–leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE galK 
rpsL (DE3) F’[lac+ lacI q pro] gor522::Tn10 trxB pRARE23 (CamR, StrR, 
TetR)
Novagen
pET-22b(+) Bacterial vector for protein expression in the periplasm, T7lac pro-
moter, AmpR
Novagen
pE35 pCR-Blunt II- Topo (Invitrogen) with enterocin CRL35 biosynthetic 
clustercloned
(Saavedra et al. 2004)
pEM05 pET-22b(+) with munA cloned This work
1INRA, Jouy-en-Josas, France. 2CERELA: Centro de Referencias para Lactobacilos. Tucumán. Argentina 3BRL, Bethesda Research Laboratories.
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the calcium chloride transformation protocol [13] and 
plasmids purified by Wizard® Plus Minipreps DNA 
Purification kit (Promega). The resultant plasmid was 
called pEM05 (Table 1). Competent cells from each 
expression host strains listed above were prepared and 
transformed following the same protocol.
2.3  Recombinant enterocin CRL35 
production
Enterocin CRL35 production was tested with all E. 
coli strains listed in Table 1 in order to find the best 
producer in LB broth. For this purpose, cells were grown 
in LB broth till OD= 0.8, then 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Genbiotech, Argentina) was 
added and cells were incubated 1 h at 37 °C with aeration. 
Anti-Listeria activities from supernatants, intracellular 
and periplasmic fractions were assayed by a modified 
spot-on-lawn assay [14]. After complete adsorption of each 
diluted sample (10 μL), TSB plates were covered with 5 ml 
of 0.6 % (w/v) agar inoculated with 106 cells of the sensitive 
strain L. innocua 7 (supplementary information for more 
details). Once E. coli Rosetta was chosen, the optimal 
concentration of inducer was selected by changing IPTG 
concentration from 0.1 to 2 mM. Afterward, bacteriocin 
synthesis was investigated in minimal media varying 
different parameters such as salt concentration, tryptone 
or yeast extract supplement, carbon source (glucose, 
glycerol), aeration and time of induction (supplementary 
information).
2.4  Recombinant enterocin CRL 35 purifica-
tion procedure
When growth conditions in minimal medium were set 
up, bacteriocinogenic E. coli Rosetta cells were grown 
till mid-log phase in 100 ml of modified M9 medium. 
Cultures were induced with IPTG and after 150 min cells 
were pelleted at 10,000 x g for 15 min. Supernatants were 
precipitated with ammonium sulfate (70 % saturation) and 
the pellet was dissolved in deionized water. Afterward, 
sample was C18 reverse-phase HPLC fractionated using 
an ÄKTA-purifier chromatography system (GE Amersham 
Pharmacia) equipped with a μBonda Pack column (10 μm 
300 x 4.6 mm Waters) and applying a non-linear gradient 
of acetonitrile. Effluents were UV monitored at 254 and 
280 nm using a multiwave detector. The active fractions 
were pooled, dried under vacuum with a Savant speed-vac 
and finally sub-fractionated by electrophoresis, according 
to the typical protocol for small peptides [15]. Purified 
bacteriocin was quantified by measuring absorbance at 
280 nm, based on the molar extinction coefficient of the 
synthetic enterocin CRL35 (Biosynthesis, TX, USA). HPLC 
purified enterocin (50 ng) was suspended in loading buffer 
without β-mercaptoethanol and kept 4 min in a boiling 
water bath. Thereafter, the gel was divided in two halves, 
one was stained with either SYPRO® Ruby Protein Gel 
Stain (Sigma) or Colloidal Coomassie Blue Brillant G-250 
[16] to visualize the bands and the other half was fixed 
with methanol: acetic acid: water (40:10:50). After fixing, 
the gel was washed with sterile double distilled water and 
placed on a TSB agar plate. Then, it was covered with 10 
mL of 0.6 % (w/v) agar inoculated with the sensitive strain 
and plate was incubated at 30 °C for 16 h.
2.5  Characterization of recombinant 
enterocin CRL35 by MS analysis
The HPLC active fraction was lyophilized and re-dissolved 
in 100 µL of 0.1% trifluoroacetic acid (TFA). Prior to MS 
analysis, an aliquot (10 µL) was further desalted by 
C18 Zip Tip® micro-columns (Millipore, Bedford, CA, 
USA). MALDI-TOF MS experiments were carried out on 
a Voyager DE-Pro spectrometer (PerSeptive BioSystems, 
Framingham, MA, USA) equipped with a N2 laser (λ = 337 
nm). Sinapinic acid (Sigma, 50 % acetonitrile (v/v) / 0.1 
% TFA), was used as the matrix. The mass spectra were 
acquired in the reflector linear ion mode using the Delayed 
Extraction (DE) technology. The instrument operated at 
an accelerating voltage of 25 kV. External mass calibration 
was performed with a commercial standard peptide 
mixture (Sigma). Raw data were elaborated using Data 
Explorer 4.0 software purchased with the spectrometer.
2.6  Reduction and Cys-alkylation of 
enterocin CRL35
An aliquot (10 µL) of the HPLC fraction of enterocin 
CRL35 was ten-fold diluted with a denaturing/reducing 
buffer (6M guanidine HCl, 75 mM Tris, 1 mM EDTA, 10 mM 
DTT, pH 8.0) and incubated 1 h at 56 °C. After reduction, 
cysteines were alkylated 40 min at room temperature in 
the dark with iodoacetamide (three-fold molar excess 
with respect to DTT). Cys-alkylated enterocin was purified 
using a C18 Zip Tip® micro-columns, dried in a speed-vac 
and analyzed by MALDI-TOF MS. 
2.7  Enzymatic proteolysis of enterocin CRL35
An aliquot of the enterocin CRL35 (10 µL) was diluted 
with 20 µl of 50 mM ammonium bicarbonate, pH 8.0, and 
incubated overnight at 37 °C with 0.2 µg of sequencing 
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grade endo-proteinase Asp-N (Roche, Mannheim, 
Germany). Reaction was stopped by freeze-drying and 
peptides were reconstituted in 20 µL of 0.1 % TFA. 
Resulting peptides were analyzed by MALDI-TOF MS, 
using the same conditions above, except for the matrix 
that was α-cyano-4-hydroxycinnamic acid (Sigma, 10 mg/
ml in 50 % acetonitrile / 0.1 % TFA, v/v). Mass values are 
reported as average MH+, except where indicated. The 
remaining Asp-N hydrolyzed peptides were analyzed with 
nanoflow HPLC-ESI MS/MS.
2.8  nanoHPLC-ESI MS/MS analysis of recom-
binant enterocin CRL35
Nanoflow HPLC separations were carried out with an 
Ultimate 3000 nano HPLC system (Dionex, Sunnydale, 
CA, USA) equipped with an autosampler. Asp-N (2 µL) 
digests of enterocin CRL 35 were loaded onto a C18 trapping 
cartridge (LC Packings, Dionex, USA) using a Famos 
autosampler (Dionex) and flushed 5 min at the flow rate 
of 5 µL/min by means of the loading pump. Separation 
was carried out using a commercial capillary column 
(PepMap, C18, 5 µm, 300 Å, 75 µm x 15 cm, LC Packings, 
Dionex) applying a linear gradient from 2% to 40% of 
solution B over 60 min, following 10 min of isocratic 
elution at 2% of solution B, at a constant flow rate of 300 
nL/min. Solvent A was H2O containing 0.1% formic acid; 
solvent B was 0.08% formic acid in 80% acetonitrile (v/v). 
Eluted peptides were analyzed on-line using an ESI-Q TOF 
Q-Star Pulsar instrument (Applied BioSystems, Foster City, 
CA, USA) equipped with a nanospray source (Protana, 
Denmark). The MS/MS fragmentation was performed 
in the information-dependent acquisition (IDA) mode. 
Precursor ions were selected for fragmentation using 
the following MS to MS/MS switch criteria: ions greater 
than m/z 400.0, charge states 2 to 4, intensity exceeds 
15 counts, former target ions were excluded for 60 s and 
ion tolerance was 50.0 mmu. CID was used to fragment 
multiple charged ions, and N2 was used as the collision 
gas. MS/MS spectra were manually assigned, with the 
aid of the GPMAW 5.1 software (Lighthouse data, Odense, 
Denmark) that calculates the mass of the peptides and 
expected fragment ions. 
3  Results
3.1  Cloning strategy for munA gene
The plasmid pET22b(+) was chosen for heterologous 
expression for two reasons. First of all, it allows the 
cloning of the target gene downstream the sequence 
encoding the signal peptide of the periplasmic protein 
PelB. Therefore, the protein of interest would be exported 
by the E. coli sec pathway to the periplasm, guaranteeing 
an easier purification as compared to proteins purified 
from cytoplasmic material. On the other hand, the cloned 
gene is under the strong promoter T7lac. Once munA was 
directionally cloned into pET22b(+) vector, the nucleotide 
sequence was analyzed by the DNA sequencing service at 
CERELA (CCT-Tucumán/CONICET). It was confirmed that 
the DNA fragment had correctly been inserted and no 
frame shifts were observed. Thus, a variant of enterocin 
CRL35 with two extra amino acids i.e. methionine and 
glycine was designed. These two amino acids come from 
the NcoI sequence utilized for cloning. In fact, signal 
peptidase would cleave the PelB signal peptide just before 
methionine. The cloned munA gene has an AGA codon 
instead of AAA as the 22nd codon of the sequence, which 
implies the conservative substitution Lys22Arg. A similar 
finding was reported by Acuña et al. when designed 
a chimeric peptide combining enterocin CRL35 and 
microcin V [17].
3.2  Purification of enterocin CRL35
Enterocin CRL35 was  precipitated from culture 
supernatant and passed through C18-HPLC as described 
in Experimental Procedures. The weak broadened peak 
(n. 2) eluted at intermediate retention time of the HPLC 
chromatogram exhibited exclusive anti-Listeria activity 
(Figure  1). On the contrary, both the peak eluted at low 
percentages of acetonitrile and the “washing peak” with 
very high retention time were inactive. In particular, the 
hydrophobic HPLC peak n. 3 contained no MS detectable 
polypeptides, but polymeric species (polyethylene) most 
likely released from the chromatographic stationary 
phase. Chromatographic fractions were further analyzed 
by SDS-PAGE. No significant amounts of contaminating 
proteins were detected with either SYPRO® Ruby or 
Comassie G-250 staining: the culture supernatant showed 
just a few faint protein bands (data not shown), which 
were expected because the culture medium was prepared 
with yeast extracts and no other protein source. It has to 
be considered that E. coli is known to not excrete many 
proteins into the modified M9 medium [18]. Most of the 
peptides present in the supernatant belonged to the yeast 
extract since sterile modified M9 medium, analyzed as 
the control, exhibited a strictly related proteinaceous 
pattern. Although enterocin CRL35 could not be stained 
by the protocols used, its presence was demonstrated by 
an activity gel assay. Indeed, an inhibition zone because 
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Figure 1: C18-HPLC purification of Enterocin CRL35. The ammonium sulfate active fraction was dissolved in deionized water and fractionated 
as described. Elution was followed at OD= 254 nm while activity was analyzed in every fraction by the spot-on-lawn assay. The inset shows 
the anti-Listeria activity assay performed with peak n. 2. This result is representative of at least 10 independent replicate purifications.
Figure 2:Recombinant enterocin CRL35 visualized by activity gel. 
The active HPLC fractions were pooled and concentrated. The 
broad range molecular weight markers were a mixture of standard 
pre-stained proteins. Inhibition zone (a) was observed after 16 h of 
incubation at 30 °C. This result is representative of three indepen-
dent experiments.
of antimicrobial activity of enterocin CRL35 against L. 
innocua 7 at about 4.5 kDa clearly appeared as shown in 
Figure 2. 
Table 2 summarizes the purification process. It 
can be observed that a 75-fold purification from M9 
culture supernatants was achieved, considering that the 
starting concentration was around 0.5 mg/ml protein 
as determined by the Lowry method [19]. On the other 
hand, 7 % of the initial activity was recovered after two 
steps of purification. Some experiments required culture 
supernatants to be boiled 10 to 20 minutes to precipitate 
large proteins and improve the purification procedure. 
However, results showed no changes in purification 
yields.. This latter result was expected since most of the 
contaminants are small peptides, which generally lack 
elements of tertiary structure and, therefore, are not 
affected by temperature.
3.3  Mass spectrometry
The MALDI-TOF analysis of the HPLC active peak exhibited 
a couple of dominant signals, with nearly comparable 
intensity, at m/z 4507.0 and 4519.0 (Figure  3A). The first 
signal is compatible with that expected for enterocin 
CRL35. The second one was deemed to correspond to 
a variant form of enterocin CRL35 that differs by 12 Da 
from the native bacteriocin,  probably  due to mutation(s) 
arisen after transformation in E. coli Rosetta. Interestingly, 
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both signals were shifted at m/z 114 Da higher (57 Da / 
carbamidomethyl group) after cys-carbamidomethylation, 
confirming that enterocin CRL35 contained two cysteins 
formerly engaged in a disulfide bond (Figure  3B). Such 
an outcome demonstrated the ability of the selected E. 
coli strain to correctly express and to post-synthetically 
process the bacteriocin, which preserved the expected 
folding ruled by the intramolecular disulfide bond. The 
minor signals appearing at lower m/z were unaffected by 
Cys-alkylation.
The enterocin CRL35 was expected to be split roughly 
in the middle by Asp-N, which specifically cleaves 
proteins at the N-terminal side of aspartate residues. 
Thus, the unreduced polypeptide was incubated with 
Asp-N and hydrolyzed peptides were analyzed again. 
The MALDI-TOF MS analysis showed three main signals: 
at m/z 1892.0, which matches the theoretical mass of 1-18 
enterocin CRL35 containing an intramolecular disulfide 
bond and the M+H+ 2628.3 and 2640.4 (monoisotopic) 
of nearly equal intensity belonging to the 19-45 peptide 
(Figure 4 and inset). The presence of these two peptides 
differing by 12 Da demonstrated that the possible amino 
acid substitutions between the enterocin variants were 
confined to the 19-45 region.
Table 2. Purification of recombinant enterocin CRL35. 
 
Total protein (mg) Total activity (AU) Specific activity (AU/mg) Yield (%) Purification
Supernatant 534 1,000 1.87 100 1
(NH4)2SO4 fraction 8 150 18.75 15 10
Peak 1 HPLC 0.5 70 140 7 75
Figure 3: MALDI-TOF MS analysis of the HPLC purified active fraction either before (A) or after (B) reduction/Cys-alkylation by iodoacetamide. 
The measured mass of the reduced enterocin demonstrates that the two cysteines are engaged in an intramolecular disulfide bond, thus 
highlighting the ability of the selected E. coli strain to correctly process the bacteriocin, at the post-synthetic level. The magnified views in 
the insets evidence the presence of two enterocin isoforms differing by 12 Da.  The minor signals at lower m/z, most likely due to interfering 
medium peptides, were unaffected by Cys-alkylation. No oligomeric forms of enterocin CRL35 were observed at higher m/z (not shown).
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When analyzed by nanoHPLC-ESI-Q-TOF MS/MS, the 
collision induced MS/MS fragmentation of the doubly-
charged ion m/z 946.9 (Figure  5) confirmed the correct 
identification of the 1-18 peptide. A partial internal sequence 
including the expected YGNV motif of enterocin CRL35, 
was inferred (Figure 5). However, the 1-18 sequence could 
not be completely reconstructed, probably owing to the 
internal disulfide bridge that limited the fragmentation of 
the proximal amino acids. On the other hand, the nanoLC-
ESI Q-TOF MS/MS analysis confirmed the presence of two 
Figure 4: MALDI-TOF MS analysis of the Asp-N digest of the HPLC peak no. 2. Peptide signals were assigned according to the predicted 
sequence of enterocin CRL 35. The 1-18 peptide (m/z 1892.0) is flanked by a smaller signal with +16 Da (m/z 1908) due to oxidized Met1. The 
dominant signals were M+H+ 2628.3 and 2640.4 (monoisotopic) of nearly equal intensity, which arose from the native and variant 19-45 
enterocin peptide.
Figure 5: MS/MS confirmation of the 1-18 peptide showing a six-amino acid internal sequence. Additional internal fragments also occur.
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peptides eluting in two closely overlapping HPLC peaks 
(triply-charged ions m/z 876.81 and 880.81, M+H+ 2628.3 
and 2640.40) which corresponded to the 19-45 peptide of 
the native and mutant enterocin CRL35, respectively. The 
collision induced MS/MS fragmentation of the m/z 876.81 
and 880.81 ions (Fig 6A and 6B) allowed to reconstruct 
significant part of the peptide sequences, demonstrating 
the effective integral expression of enterocin CRL35 
by E. coli Rosetta and the simultaneous production of 
a mutant form carrying two amino acid substitutions, 
namely proline instead of glycine at position 21 and 
lysine replacing the arginine 22 (P21-K22 à G21-R22). The 
expected mass difference for such a double replacement 
is 12 Da that also matches the difference recorded between 
the unhydrolyzed variants. In order to confirm this 
finding, plasmid DNA was purified from 5 ml culture of 
bacteriocinogenic E. coli Rosetta, 2.5 h after induction with 
IPTG, PCR-amplified using T7 promoter and terminator 
Figure 6: MS/MS collision induced decay (CID) of the triply-charged ions m/z 876.81 (A) and 880.81 (B). The sequence reconstruction of 
the y- and b- fragmentation series allowed inferring the two peptide sequences. The peptides differ by a double amino acid substitution: 
G21-R22 à P21-K22.
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primers and munA gene was thus sequenced. It was found 
that the 21st codon of munA was present as the expected 
GGA (Gly) but also as CCA, which encodes for proline. 
In the same trend, AGA was found to be the 22nd codon 
but AAA was also detected, which implies the mutation 
R22K. Therefore, the double amino acid substitution in 
this new enterocin CRL35 variant is the result of a triple 
base mutation in the munA structural gene present in the 
pEM05 plasmid. Based on these results, it is probably that 
two subpopulations of E. coli Rosetta are present i.e. one 
group of cells that produces the expected enterocin CRL35 
variant (Lys22Arg mutation and two extra amino acids at 
the N-terminus), and cells that express another variant 12 
Da larger.
4  Discussion
One of the first attempts for the heterologous expression of 
bacteriocins in E. coli was reported 15 years ago by Miller 
et al., who fused the pediocin PA-1 structural gene with the 
maltose-binding protein and used a periplasmic leaky E. 
coli host [20]. The main scope of that pioneering work was 
not to over-express pediocin PA-1 for further structural and 
activity studies but to investigate the secretion process of 
that peptide. In fact, their approach had several pitfalls 
such as a leaky synthesis even in the absence of IPTG. In 
addition, the fusion protein could not be cleaved in order 
to release the mature bacteriocin upon secretion [20]. 
However, this study clearly showed that E. coli was indeed 
a good host for LAB bacteriocins and that they could be 
secreted via the sec machinery.
In this regard, it should be noted that there are several 
bacteriocins from lactic bacteria that can be exported by 
the general secretion pathway such as hiracin JM79 [21], 
divergicin A [22], acidocin B [23] and enterocin P [24]. 
Moreover, enterocin P was already successfully expressed 
in E. coli and exported by its own signal peptide, which 
was recognized by the general secretion machinery of E. 
coli [25]. Nowadays, there is a growing number of reports 
on the heterologous expression of bacteriocins in E. coli. 
Each approach has its own advantages and disadvantages 
[25–32]. 
In the present work, enterocin CRL35 has been 
expressed fused to the C-terminus of PelB signal sequence. 
Even though the peptide was thought to be confined to 
the periplasm, enterocin was mainly recovered from the 
culture supernatant. No extra manipulation of munA was 
needed since the host strain contained universal tRNAs, 
thus guaranteeing optimal synthesis of this heterologous 
peptide. The purification protocol presented here allowed 
a straightforward purification of the bacteriocin from the 
medium. However, it was found that the final sample 
had lower specific activity as compared to the pure 
synthetic peptide [7]. In fact, peptide was obtained at a 
final concentration of approximately 100 µM, considering 
0.5 mg of pure bacteriocin per liter, but the activity was 
similar to that displayed by 10 µM of synthetic peptide 
(data not shown). 
The converging indications of 1) the exact matching 
of the peptide MW as confirmed by MALDI-TOF analysis, 
2) the specific cleavage by Asp-N, which releases the 
predicted fragments with the exact theoretical masses, 
3) the presence of two cysteine residues that are engaged 
in a disulfide bond (confirmed by the analysis after 
reduction/alkylation) and 4) the identity of MS/MS 
fragment ions, undoubtedly prove that our enterocin 
CRL35 variant was indeed produced by E. coli Rosetta 
(with the Lys22Arg substitution as pointed out in the 
Results section). However, the MS studies also identified 
an additional enterocin CRL35 variant that had two amino 
acid substitutions with respect to the starting enterocin 
i.e. Gly21Pro and Arg22Lys. Since the munA sequence in 
pEM05 plasmid was verified and no errors were found, the 
mutations leading to those substitutions had to arise in 
one subpopulation of E. coli Rosetta . The mutant peptide 
may be responsible for the low specific antimicrobial 
activity detected. Even though enterocin CRL35 does 
not behave as a suicide probe, its production may pose 
a problem for E. coli, such as the partial dissipation of 
the proton-motive force. Indeed, a slight decrease in 
E. coli Rosetta survival was observed upon induction 
with either IPTG or lactose. Since enterocin CRL35 was 
mainly recovered from the extracellular medium rather 
than the periplasmic compartment, it can be argued that 
enterocin has to permeate the outer membrane of E. coli 
perhaps by partial disruption of the periplasmic leaflet 
of the outer membrane. This would imply that a similar 
disruption of the inner membrane may take place as 
well. Anyways, mutations that lead to less harmful or 
inactive heterologous proteins are not uncommon for BL21 
derivatives. Consistently, the enterocin CRL35 variant we 
characterized has a proline instead of glycine, which might 
imply a major change in the bacteriocin tridimensional 
structure upon binding to membranes. As was previously 
shown for leucocin A and carnobacteriocin B2, C-terminus 
of pediocin-like bacteriocins may form a helical structure 
just after the disulfide bond [33, 34]. The occurrence of a Pro 
at the position 22 might definitively prevent the functional 
bacteriocin folding upon interaction with membranes. 
It can be speculated that the mutant enterocin would 
disrupt the pore structure at the Listeria membrane, which 
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is thought to be the key step in the bacteriocin mechanism 
of action. This is the first time that a mutant of pediocin-
like bacteriocins co-expressed in E. coli is reported. More 
strikingly, two amino acids were changed in the enterocin 
variant as a consequence of three point mutations in 
the enterocin CRL35 structural gene, which is a highly 
unusual event. This outcome suggests the possibility of 
carrying out detailed relevant structure-function studies.
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Supplementary information
Selection of the best host for heterologous 
expression of enterocin CRL35 
A number of possible hosts for heterologous expression 
of enterocin CRL35 were tested in order to select the most 
suitable strain for bacteriocin production. Several E. coli 
host were selected: E. coli BL21 is a protease-defective 
strain widely used for heterologous expression. E. coli C41 
and E. coli C43 are BL21 derivatives that were isolated as 
clones that efficiently expressed toxic proteins (1). On the 
other hand, E. coli Rosetta is another BL21-derived strain 
that has a plasmid encoding rare 
E. coli codons, allowing the normal synthesis of 
heterologous proteins from almost all sources without 
needing further genetic manipulations. E. coli Origami 
strain is a double mutant in thioredoxin reductase and 
glutathione reductase with an oxidizing cytoplasm that 
allows disulfide bond formation. Finally, E. coli Rosetta-
gami 2 is a combination between Origami and Rosetta 
strains, thus displaying both features: a universal 
translation and an oxidizing cytoplasmic environment. 
Interestingly, anti-Listeria activity was present not only 
in the periplasm fractions but also mainly in the culture 
supernatants as though the peptide could permeate 
the outer-membrane in all the strains tested. However, 
important differences in enterocin CRL35 production were 
found among them (Fig. S1). 
The fact that E. coli Rosetta and E. coli Rosetta-gami 2 
were the best strains is not surprising since they are able 
to synthesize proteins from all sources with no differences 
because of “rare” codons. In fact, enterocin CRL35 gene 
has the codon GGA repeated four times as well as the 
codon AGA, as it was mentioned above. Both codons are 
infrequent in E. coli and this issue would be a potential 
problem for heterologous expression of this bacteriocin in 
E. coli (2). Even though E. coli Rosetta gami 2 is a suitable 
strain for producing enterocin CRL35, it has a major 
drawback: its growth rate is extremely slow (3). 
Moreover, since this peptide is secreted into the 
periplasm and eventually into the culture medium, 
there is no need for assuring intracellular disulfide bond 
formation. For these reasons, E. coli Rosetta was chosen as 
the producing strain. 
It is important to stress that even though no important 
changes in cell survival were found during enterocin 
CRL35 expression, a slight decrease in cell viability was 
seen for all producing strains (data not shown). As it can 
be seen in Fig. S2, the optimal concentration of IPTG was 
1 mM. 
Figure S1: Expression of enterocin CRL35 in different E. coli strains. 
Cells were grown in LB medium till mid-log phase at 37 °C. Then, 
they were induced with 0.5 mM IPTG and supernatants were coll-
ected by centrifugation. 10 μL of different dilutions of each sample 
were spotted onto TSB plates and L. innocua 7 was seeded into soft 
agar. A: E. coli Rosetta, B: E. coli C41, C: E. coli Origami, D: E. coli 
BL21, E: E. coli C43, F: E. coli Rosetta-gami 2. The plate shown is 
representative of at least 5 independent experiments. 
Figure S2: Induction of enterocin CRL35 synthesis. E. coli Rosetta 
was grown in LB till mid-log phase and induced with 0.2, 0.5, 1 and 
2 mM IPTG. Culture supernatants were collected by centrifugation 
and inhibition halos were visualized as described in materials and 
methods by the spot-on-lawn assay. The plate shown is representa-
tive of at least 5 independent experiments. 
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Because enterocin CRL35 was able to cross the outer-
membrane and therefore reach the culture medium, the 
purification had to be focused in this fraction. Enterocin 
production was tested in M9 (Sigma) as well as in MT 
medium (4). Since no significant difference was found 
between these two media, M9 was selected because M9 
base can be obtained ready to use from the purchaser. 
Supplements such as tryptone, yeast extract and NaCl were 
added at different final concentrations and strains were 
induced with 1 mM IPTG. Finally, the chosen condition 
for enterocin CRL35 expression in M9 medium was: 0.6 % 
glycerol, 0.1 % yeast extract, 1 % NaCl, 1 mM IPTG with 
an induction time of 150 minutes. 37 °C turned out to be 
better than the usual 30 °C for heterologous expression. 
Even though anti-Listeria activity was always higher 
in LB medium, the modified M9 medium allowed an 
acceptable production. In addition, it was found that 
supplementation of 10 mM EDTA and 0.05 % tween 20 
at the time of induction significantly increased the final 
yield. It can be hypothesized that these chemicals would 
enhance the permeation of enterocin CRL35 through the 
outer-membrane of E. coli (5). 
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